Cellulitis | Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department
Cellulitis research study
What is the primary objective of this study?
Patients often come to the emergency department with bacterial skin infections (known as \"cellulitis\"). Some patients with very severe infections are admitted to hospital for antibiotic treatment and some are sent home on oral antibiotics. Many patients have moderate infections and are treated as outpatients with daily intravenous antibiotics for 2-5 days. In this patient group it is unclear if treatment with oral antibiotics is as effective as intravenous antibiotics. The purpose of this study is to determine if treatment of moderate cellulitis with an intravenous antibiotic (cefazolin) for 3-5 days is as effective as treatment with an oral antibiotic (moxifloxacin). We hypothesize that the oral agent will be as effective as intravenous treatment for moderate cellulitis.
Who is eligible to participate?
Inclusion Criteria: - Cellulitis requiring outpatient intravenous antibiotic therapy; - ability to understand,/sign informed consent; - no contraindications to study medications, - not pregnant/breastfeeding Exclusion Criteria:
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Cefazolin and MoxifloxacinSee Detailed Description.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: January 2004
Completed Date: December 2013
Phase: Phase 3
Primary Outcome: Clinical cure at 7 days
Secondary Outcome: Area of erythema (Days 0, 1, 2, 3, 4, 5, 6, 7), days of treatment, side-effects of medication, cost of treatment, patient satisfaction, relapse at 14 days
Study sponsors, principal investigator, and references
Principal Investigator: Rob Stenstrom, MD
Lead Sponsor: University of British Columbia